leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...6566676869707172737475...235236»
  • ||||||||||  MODULE 3: Evidence-Based Selection and Sequencing of Therapy for Patients with mCRC (San Francisco Marriott Marquis, Golden Gate Ballroom, Salon A (B2 Level)) -  Dec 23, 2022 - Abstract #ASCOGI2023ASCO_GI_998;    
    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Exelixis Inc, Lilly, Natera Inc, and Seagen Inc. Correlation between the location of the primary tumor (right versus left side) and outcomes with EGFR antibody-based regimens among patients with mCRC Correlation between the location of the primary tumor and outcomes with EGFR antibody-based regimens among patients with mCRC Design, eligibility criteria and key findings from the Phase III PARADIGM trial evaluating mFOLFOX6 with either panitumumab or bevacizumab as first-line therapy for RAS wild-type mCRC; implications for treatment Factors in selecting and sequencing regorafenib, TAS-102 and anti-EGFR therapy for progressive mCRC; utility of rechallenge with EGFR antibodies after disease progression Long-term findings from pivotal Phase III trials assessing regorafenib and TAS-102 for patients with multiregimen-relapsed CRC Long-term findings from pivotal Phase III trials assessing regorafenib and TAS-102 for patients with multiregimen-relapsed mCRC Patient selection for and practical considerations, including optimal dosing, with the use of regorafenib for mCRC Available data with TAS-102 in combination with bevacizumab for patients with mCRC; emerging findings from the Phase III SUNLIGHT trial and implications for clinical practice
  • ||||||||||  botensilimab (AGEN1181) / Agenus
    Enrollment open:  A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer (clinicaltrials.gov) -  Dec 23, 2022   
    P2,  N=78, Recruiting, 
    Systemic therapies adopted in real life practice are sophisticated with various combination modality and different sequences. Not yet recruiting --> Recruiting
  • ||||||||||  5-fluorouracil / Generic mfg.
    Review, Journal, PARP Biomarker, Metastases:  Maintenance chemotherapy in advanced and metastatic pancreatic cancer, a narrative review and case series. (Pubmed Central) -  Dec 22, 2022   
    Median progression-free survival is 22.13 months which is higher than that reported in the literature, which ranges between 5 and 10.6 months. Although further conclusions cannot be drawn because of the small sample size, the results are promising and encourage further exploration of this topic in larger prospective trials.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Cetuximab severe cutaneous toxicity… a gateway for bacteremia: case report. (Pubmed Central) -  Dec 21, 2022   
    A 57-year-old woman with metastatic adenocarcinoma of the colon, receiving FOLFIRI and Cetuximab as a first-line treatment, presented with a severe erythematous rash and xerosis resistant to local treatment with moisturizing emollients...This is a life-threatening cutaneous toxicity of cetuximab with secondary bacterial infection. Early recognition of cutaneous side effects of EGFR inhibitors is important to prevent such type of toxicities.
  • ||||||||||  Hepacid (pegargiminase) / Polaris Pharma
    Journal:  WWOX-rs13338697 genotype predicts therapeutic efficacy of ADI-PEG 20 for patients with advanced hepatocellular carcinoma. (Pubmed Central) -  Dec 20, 2022   
    The WWOX-rs13338697-GG genotype was associated with lower tissue WWOX and ASS1 levels and higher pretreatment plasma arginine levels, resembling an arginine auxotrophic phenotype requires excessive extracellular arginine supply. Silencing WWOX to mimic HCC with the WWOX-rs13338697-GG genotype further stimulated HCC cell response to hypoxia through increased HIF1A expression, leading to further reduction of ASS1 and thus increased cell susceptibility to ADI-PEG 20.
  • ||||||||||  Review, Journal:  État des lieux des pratiques de prise en charge des cancers des voies biliaires en France : résultats de l'enquête nationale ACABi. (Pubmed Central) -  Dec 20, 2022   
    For non-operable tumors, the most commonly used first-line chemotherapy was cisplatin/gemcitabine (CISGEM, 66.3%)...The most commonly used second-line treatment was 5FU/oxaliplatin (FOLFOX, 52.3%). Molecular profiling was performed in more than half of the patients for 41.1% of respondents in group A and 18.8% in group B. This survey shows the application of therapeutic standards but also certain practices diverging from the recommendations as well as disparities between centers.
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Trial completion date, Trial primary completion date, Monotherapy:  CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) -  Dec 20, 2022   
    P1b/2,  N=1143, Recruiting, 
    Molecular profiling was performed in more than half of the patients for 41.1% of respondents in group A and 18.8% in group B. This survey shows the application of therapeutic standards but also certain practices diverging from the recommendations as well as disparities between centers. Trial completion date: Oct 2026 --> Jun 2027 | Trial primary completion date: Aug 2024 --> Dec 2024
  • ||||||||||  Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Cytotoxic Chemotherapy for Biliary Tract Cancers (2F Room 201DEF) -  Dec 18, 2022 - Abstract #APASL2023APASL_78;    
    Recently, a Japanese phase III study demonstrated a statistically significant survival advantage for adjuvant therapy with S-1. Under these circumstances, several large-scale trials are now underway to determine the clinical roles of novel perioperative treatment strategies, including the efficacies of chemotherapy, molecular targeted therapy, and immunotherapeutic agents administered either as single agents or in combination with other agents.
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
    Trial completion date, Trial primary completion date:  LyRICX: Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer (clinicaltrials.gov) -  Dec 16, 2022   
    P2,  N=310, Recruiting, 
    These findings support the use of short-course neoadjuvant chemotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma. Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2022 --> Aug 2024